Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study of possible anticancer drug reveals new mechanism of gene regulation

20.12.2002


Researchers at Washington University School of Medicine in St. Louis have discovered a possible new mechanism for regulating large groups of genes. While conducting yeast research on a potential new anticancer drug, the team identified a mechanism that enables the genome to silence large numbers of genes simultaneously, rather than each gene individually.



The finding emerged during research studying the molecular action of the drug rapamycin. Rapamycin currently is used to suppress the immune system following kidney transplantation, but it also is being investigated as a promising anticancer drug. Rapamycin stops tumor-cell growth through a mechanism unlike those used by other anticancer drugs. The findings are published in the December issue of Molecular Cell.

"This study shows how basic research can have a clinical impact," says study leader X. F. Steven Zheng, Ph.D., assistant professor of pathology and immunology. "It gives us insights into the molecular mechanism of rapamycin’s antitumor activity and may provide new targets for drug development."


As an immunosuppressant, rapamycin is different from other drugs. While other immunosuppressants tend to promote the growth of cancer cells, rapamycin blocks the proliferation of tumors. In addition, rapamycin blocks the development of blood vessels in tumors, a process known as angiogenesis. These features led doctors to test its use as an anticancer drug.

"For a single drug to block both tumor proliferation and angiogenesis is unique," says Zheng, who is an investigator with the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

Test-tube experiments done by others showed that rapamycin binds to a large, previously unknown cell protein known as target of rapamycin (TOR). TOR is found in organisms from yeast to humans, suggesting that it may serve an essential purpose in cells.

Zheng and colleagues used rapamycin to inactivate TOR, enabling them to examine both TOR’s function in the cell and how rapamycin works.

The researchers identified about 300 yeast genes involved in TOR-related activities. The product of one of these genes, a protein known as silent information regulator 3 (Sir3), normally clings to a battery of genes responsible for a stress protein, thereby keeping the genes inactive and silent. Stress proteins are molecules produced by cells during adverse growing conditions.

But the researchers found that when rapamycin inactivates TOR, Sir3 molecules detach from the line of stress-protein genes, triggering a stress response: The cells begin producing stress proteins, their walls thicken and they stop proliferating.

"This surprised us," Zheng says. "TOR was not known to be directly involved in stress control. Also, this means of silencing many genes simultaneously suggests a new type of gene regulation." Usually, genes are turned on or off individually by proteins targeted to specific genes, he says.

Furthermore, the investigators found that when rapamycin inactivates TOR, it also shuts down nutrient processing pathways, preventing yeast cells from using glucose to produce energy and amino acids to make new proteins.

Overall, the researchers conclude that when rapamycin inhibits TOR, it triggers a variety of responses, including stress and starvation responses. Together, these actions probably cause the cells to stop proliferating.

These insights into rapamycin’s action must now be verified in human cells.


Ai W, Bertram PG, Tsang CK, Chan T-F, Zheng XFS. Regulation of subtelomeric silencing during stress response. Molecular Cell, December 2002.

Funding from the National Institutes of Health supported this research.

Darrell E. Ward | EurekAlert!
Further information:
http://medinfo.wustl.edu/

More articles from Health and Medicine:

nachricht Custom-tailored strategy against glioblastomas
26.09.2016 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New leukemia treatment offers hope
23.09.2016 | King Abdullah University of Science and Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First-Ever 3D Printed Excavator Project Advances Large-Scale Additive Manufacturing R&D

Heavy construction machinery is the focus of Oak Ridge National Laboratory’s latest advance in additive manufacturing research. With industry partners and university students, ORNL researchers are designing and producing the world’s first 3D printed excavator, a prototype that will leverage large-scale AM technologies and explore the feasibility of printing with metal alloys.

Increasing the size and speed of metal-based 3D printing techniques, using low-cost alloys like steel and aluminum, could create new industrial applications...

Im Focus: New welding process joins dissimilar sheets better

Friction stir welding is a still-young and thus often unfamiliar pressure welding process for joining flat components and semi-finished components made of light metals.
Scientists at the University of Stuttgart have now developed two new process variants that will considerably expand the areas of application for friction stir welding.
Technologie-Lizenz-Büro (TLB) GmbH supports the University of Stuttgart in patenting and marketing its innovations.

Friction stir welding is a still-young and thus often unfamiliar pressure welding process for joining flat components and semi-finished components made of...

Im Focus: First quantum photonic circuit with electrically driven light source

Optical quantum computers can revolutionize computer technology. A team of researchers led by scientists from Münster University and KIT now succeeded in putting a quantum optical experimental set-up onto a chip. In doing so, they have met one of the requirements for making it possible to use photonic circuits for optical quantum computers.

Optical quantum computers are what people are pinning their hopes on for tomorrow’s computer technology – whether for tap-proof data encryption, ultrafast...

Im Focus: OLED microdisplays in data glasses for improved human-machine interaction

The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP has been developing various applications for OLED microdisplays based on organic semiconductors. By integrating the capabilities of an image sensor directly into the microdisplay, eye movements can be recorded by the smart glasses and utilized for guidance and control functions, as one example. The new design will be debuted at Augmented World Expo Europe (AWE) in Berlin at Booth B25, October 18th – 19th.

“Augmented-reality” and “wearables” have become terms we encounter almost daily. Both can make daily life a little simpler and provide valuable assistance for...

Im Focus: Artificial Intelligence Helps in the Discovery of New Materials

With the help of artificial intelligence, chemists from the University of Basel in Switzerland have computed the characteristics of about two million crystals made up of four chemical elements. The researchers were able to identify 90 previously unknown thermodynamically stable crystals that can be regarded as new materials. They report on their findings in the scientific journal Physical Review Letters.

Elpasolite is a glassy, transparent, shiny and soft mineral with a cubic crystal structure. First discovered in El Paso County (Colorado, USA), it can also be...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Paper – Panacea Green Infrastructure?

30.09.2016 | Event News

HLF: From an experiment to an establishment

29.09.2016 | Event News

European Health Forum Gastein 2016 kicks off today

28.09.2016 | Event News

 
Latest News

First-Ever 3D Printed Excavator Project Advances Large-Scale Additive Manufacturing R&D

30.09.2016 | Materials Sciences

New Technique for Finding Weakness in Earth’s Crust

30.09.2016 | Earth Sciences

Cells migrate collectively by intermittent bursts of activity

30.09.2016 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>